GFS Advisors LLC Takes $96,000 Position in Haleon plc (NYSE:HLN)

GFS Advisors LLC acquired a new position in Haleon plc (NYSE:HLN) in the 4th quarter, HoldingsChannel reports. The fund acquired 10,025 shares of the company’s stock, valued at approximately $96,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in shares of Haleon by 2.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,007,458 shares of the company’s stock worth $8,322,000 after purchasing an additional 24,673 shares in the last quarter. Hsbc Holdings PLC grew its stake in Haleon by 132.6% in the 2nd quarter. Hsbc Holdings PLC now owns 35,876 shares of the company’s stock valued at $296,000 after buying an additional 20,449 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Haleon by 12.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 13,281 shares of the company’s stock valued at $110,000 after buying an additional 1,450 shares in the last quarter. Truist Financial Corp raised its holdings in Haleon by 4.9% during the 2nd quarter. Truist Financial Corp now owns 757,133 shares of the company’s stock valued at $6,254,000 after acquiring an additional 35,456 shares during the period. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Haleon during the second quarter worth $1,658,000. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Down 1.1 %

HLN opened at $9.47 on Friday. The firm has a market capitalization of $42.85 billion, a P/E ratio of 27.84, a price-to-earnings-growth ratio of 2.71 and a beta of 0.29. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company has a fifty day moving average price of $9.54 and a 200-day moving average price of $9.75. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, October 31st. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.74 billion. During the same period in the previous year, the business earned $0.10 earnings per share. Equities research analysts expect that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HLN has been the subject of several recent research reports. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.